# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 t...
2024 Financial Guidance: Based on strong execution and significant momentum across the business, Bioventus is raising financia...
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.07) by 2...
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...